Fig. 2: Characterization of rVSV-∆G-spike.
From: A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge
a A table summarizing the genome analysis of several passages of rVSV-∆G-spike, showing elimination of VSV-G over time, together with increased titer, and formation of plaques. NA not applicable. “-” not evaluated. b Representative immunofluorescence images of Vero E6 cells infected with early passage (P5)-rVSV-∆G-spike, or late passage (P13)-rVSV-∆G-spike, stained with a SARS-CoV-2 antibody (green), and counterstained with DAPI for nuclei staining (blue). Bottom panels show insets at large magnification. Scale bars: 50 µm. rVSV-∆G-spike at P5 formed syncitia, whereas P13 showed individual infected cells, with no evidence of syncitia. c Transmission electron micrographs of P14 rVSV-∆G-spike (top panels) compared to WT-VSV (bottom panels). Right panels show immunogold labeling using gold nanoparticles conjugated antibodies directed to the spikes’ RBD. Data for b and c are representative of four and five experiments, respectively.
